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Global dissemination and implementation of behavioural 
activation
In The Lancet, David Richards and colleagues1 present 
the Cost and Outcome of Behavioural Activation versus 
Cognitive Behavioural Therapy for Depression (COBRA) 
trial—one of the largest randomised controlled trials 
so far of psychotherapy for depression—comparing 
junior, low-cost mental health workers delivering a 
simple treatment (behavioural activation [BA]) to 
experienced psychological therapists delivering the 
gold-standard treatment (cognitive behavioural therapy 
[CBT]). Results identiﬁ ed BA as non-inferior to (mean 
diﬀ erence 0·1 Patient Health Questionnaire 9 points 
[95% CI –1·3 to 1·5], p=0·89) and more cost-eﬀ ective 
than (incremental cost-eﬀ ectiveness ratio –£6865) 
CBT. Both treatments performed well, with responses 
consistent with those from a previous meta-analysis of 
treatment eﬃ  cacy.2 Therapists in three diﬀ erent routine 
UK care settings provided treatment, and exclusion 
criteria were minimal and representative of practice. 
The study is generalisable to many mental health-
care settings in the UK. Countries like the UK, where 
government-funded health care and clear evidence-
based practice guidelines exist, as well as large health-
care organisations internationally, should take note.
Stakeholders should understand that the COBRA trial 
results are not surprising. The promise of BA—that it can 
produce equivalent if not superior outcomes to more 
complex treatments and can do so more eﬃ  ciently and 
cost-eﬀ ectively—has been in place since BA’s inception, 
and results consistent with this promise have been 
accruing for decades.3 Findings from several trials show 
that BA can be applied eﬀ ectively by providers with low 
levels of training in low-resource settings, including in 
India,4 Iran,5 and Iraq,6 with low-income Latinos in the 
USA,7 and with old veterans via telemedicine.8 WHO 
has identiﬁ ed BA as a recommended treatment for 
depression in low-resource settings.9
Scientiﬁ c caution is advised, however, when 
considering large-scale global dissemination of BA. 
Substantial obstacles to successful international 
dissemination and implementation of any evidence-
based practice exist at multiple provider, patient, 
organisational, and sociopolitical levels beyond 
the scope of the COBRA trial.10 Common obstacles 
include lack of training and support for providers, 
patients’ low acceptability of and stigma towards 
treatment, organisational climates and cultures that 
are incompatible with evidence-based practices, and 
an absence of governmental policies and support 
for mental health service delivery. BA is a promising 
treatment to consider in international research eﬀ orts 
to overcome these obstacles.
BA’s face validity is crucial and might help it address 
some implementation obstacles. For example, BA’s cross-
cultural ﬁ t and adaptability, an issue not addressed in 
the COBRA trial (the study’s 91% white British sample is 
representative of the UK, but not the rest of the world), 
might be strong. The fundamental rationale behind 
BA—the importance of engagement in value-driven 
and meaningful activities as a response to adversity 
and despair—is recognised globally and has been for a 
long time. We have found BA’s rationale to be easy for 
culturally diverse patients to accept, including patients 
for whom a medical model of depression might be 
incompatible with cultural beliefs.11 Although rooted in 
medical science, BA does not need to be explained in such 
terms to patients. The message from the provider to the 
patient, simply put, could be: “Life will inevitably throw 
obstacles at you, and you will feel down. When you do, 
stay active. Do not quit. I will help you get active again.” 
When deﬁ ning activation targets, a patient’s cultural, 
spiritual, and other personal values could be incorporated 
into treatment by the provider without compromising 
BA’s core strategies or mechanism of action. Thus, when 
the goal is wide dissemination and implementation 
across cultures and settings, BA might be considered 
acceptable and appropriate by multilevel stakeholders 
(eg, patients, providers, and organisational leaders).12
The cost-eﬀ ectiveness of BA in the COBRA trial was 
driven primarily by the low costs of BA providers. Because 
BA’s rationale, techniques, and core mechanism are 
straightforward and face valid, an additional beneﬁ t of BA 
is that costs of training these providers might be low as 
well. Considering the few ﬁ nancial and human resources 
available to mental health services in many parts of the 
world, research into scalable and cost-eﬀ ective training 
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The careful study by Andreas Cipriani and colleagues 
in The Lancet1 has disturbing implications for clinical 
practice, concluding as it does that the risk–beneﬁ t 
proﬁ le of antidepressants in the acute treatment of 
depression does “not seem to oﬀ er a clear advantage for 
children and adolescents”. 
The case for antidepressants, including ﬂ uoxetine, is, 
in fact, even weaker than their meta-analysis suggests. 
The authors do express appropriate scepticism about 
the quality and potential bias of data analysed. But, 
they were not able to factor in the additional problems 
and consequences of probable data misrepresentation 
by the companies that did the primary studies. While 
the common manoeuvre of changing nominated 
primary outcomes would not have an impact on the 
ﬁ ndings from this meta-analysis, other manipulations 
will, such as failing to exclude unblinded patients from 
the eﬃ  cacy analysis.2
Similarly, although discontinuation due to 
adverse events is a relatively hard outcome, it can 
be underestimated in published papers and clinical 
study reports because of miscoding.3 Furthermore, the 
suicidal event data available to Cipriani and colleagues 
are likely to be substantially underestimated in 
the drug groups. In four trials of paroxetine versus 
placebo, only 13 (3%) of 413 events were reported in 
the paroxetine group; this seems implausible when 
individual patient-level data reanalysis of just one of 
those studies found ten events in only 93 patients 
given paroxetine (10·8%).3
So what are the implications for clinicians? Every 
decision about whether and what to prescribe needs 
a complex and partly intuitive calculation of the 
balance between harms and beneﬁ ts according to the 
patient’s circumstances. With research evidence as an 
important part of that calculation, we now know that 
we need to make a conscious correction for favourable 
misrepresentation of outcomes in published and 
unpublished study reports. A reduction should be 
applied to the reported beneﬁ t of a drug, while 
Antidepressants fail, but no cause for therapeutic gloom
Research into these and other potential strengths of 
BA in the context of implementation science is necessary 
for the hope and promise oﬀ ered by the COBRA trial 
to be fulﬁ lled. Now that we have support for BA as a 
treatment that is clinically eﬀ ective and cost-eﬀ ective, 
we can shift our eﬀ orts to focus on what is necessary 
to produce sustainable large-scale BA implementation 
across diverse geographical and cultural settings.14
*Jonathan W Kanter, Ajeng J Puspitasari
Department of Psychology, University of Washington, Seattle, 
WA 98195, USA (JWK); and Department of Psychological and 
Brain Sciences, Indiana University, Bloomington, IN, USA (AJP)
jonkan@uw.edu
We declare no competing interests. 
Copyright © Kanter et al. Open Access article distributed under the terms of CC BY.
1 Richards DA, Ekers D, McMillan D, et al. Cost and Outcome of Behavioural 
Activation versus Cognitive Behavioural Therapy for Depression (COBRA): 
a randomised, controlled, open-label, non-inferiority trial. Lancet 2016; 
published online July 22. http://dx.doi.org/10.1016/
S0140-6736(16)31140-0
2 Amick HR, Gartlehner G, Gaynes BN, et al. Comparative beneﬁ ts and harms 
of second generation antidepressants and cognitive behavioral therapies in 
initial treatment of major depressive disorder: systematic review and 
meta-analysis. BMJ 2015; 351: h6019.
3 Dimidjian S, Barrera M Jr, Martell C, Muñoz RF, Lewinsohn PM. The origins 
and current status of behavioral activation treatments for depression. 
Annu Rev Clin Psychol 2011; 7: 1–38. 
4 Chowdhary N, Anand A, Dimidjian S, et al. The Healthy Activity Program lay 
counsellor delivered treatment for severe depression in India: systematic 
development and randomised evaluation. Br J Psychiatry 2016; 208: 381–88. 
5 Moradveisi L, Huibers MJ, Renner F, Arasteh M, Arntz A. Behavioural 
activation v. Antidepressant medication for treating depression in Iran: 
randomised trial. Br J Psychiatry 2013; 202: 204–11. 
6 Bolton P, Bass JK, Zangana GA, et al. A randomized controlled trial of 
mental health interventions for survivors of systematic violence in 
Kurdistan, Northern Iraq. BMC Psychiatry 2014; 14: 360. 
7 Kanter JW, Santiago-Rivera AL, Santos MM, et al. A randomized hybrid 
eﬃ  cacy and eﬀ ectiveness trial of behavioral activation for Latinos with 
depression. Behav Ther 2015; 46: 177–92. 
8 Egede LE, Acierno R, Knapp RG, et al. Psychotherapy for depression in older 
veterans via telemedicine: a randomised, open-label, non-inferiority trial. 
Lancet Psychiatry 2015; 2: 693–701. 
9 WHO. WHO mhGAP Guideline Update. Geneva: World Health Organization, 
2015 .
10 Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. 
Fostering implementation of health services research ﬁ ndings into 
practice: a consolidated framework for advancing implementation science. 
Implement Sci 2009; 4: 50.
11 Mir G, Meer S, Cottrell D, McMillan D, House A, Kanter J. 
Adapted behavioural activation for the treatment of depression in 
Muslims. J Aﬀ ect Disord 2015; 180: 190–99. 
12 Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation 
research: conceptual distinctions, measurement challenges, and research 
agenda. Adm Policy Ment Health 2011; 38: 65–76. 
13 Puspitasari A, Kanter JW, Murphy J, Crowe A, Koerner K. Developing an 
online, modular, active learning training program for behavioral activation. 
Psychotherapy 2013; 50: 256. 
14 Powell BJ, Waltz TJ, Chinman MJ, et al. A reﬁ ned compilation of 
implementation strategies: results from the Expert Recommendations for 





See Articles page 881
JG
I/J
am
ie
 G
ril
l/G
et
ty
 Im
ag
es
